NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/03/2026
Back to search
Official data from USPTO
KAMADA EACH LIFE IS UNIQUE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KAMADA EACH LIFE IS UNIQUE
ST13
US500000099333233Class
5
Filing
99333233
Registration
8161176
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
03/03/2026
Trademark type
Word
Nice classes
5
Filing date
08/12/2025
Registration date
03/03/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/03/2026
Last transaction
03/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2017-04-00
First use in commerce
2017-04-00
Drawing code
4
Owner type
99
Owner location
Rehovot, IL
Examiner
FOSDICK, GEOFFREY A
Law office
M20
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
KAMADA LTD.
Representatives
Ben Natter Haug Partners, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals namely plasma derived and recombinant immunoglobulins for use in the treatment of infectious diseases including CMV diseaseHepatitis BVaricella ZosterrabiesHematologic conditions including Idiopathic Thrombocytopenic Purpura (ITP). Respiratory conditions including Alpha-1 Antitrypsin DeficiencyObstetrics and Gynecology (OBGYN) conditions such as hemolytic disease of the newbornTransplantation treatments including solid-organ transplants and hematopoietic stem-cell transplantation (HSCT); pharmaceuticals namely plasma derived and recombinant proteins for treating pulmonary diseasescongenital Alpha-1 Antitrypsin deficiencypost-exposure prophylaxis against viral infectionpreventing and treating immune tolerance based diseasestreating immunological disorders and treating inflammatory diseases; pharmaceuticals namely coagulation factors for bleeding disorders; plasma-derived protein preparations for therapeutic use; vaccines; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for the treatment or prevention of thrombo-embolic disorders; pharmaceutical preparations for anesthesia analgesia for surgery; pharmaceutical preparations for treatment of CMV infection and disease; pharmaceutical preparations for the treatment of Varicella Zoster Virus; pharmaceutical preparations for treatment of Hepatitis; pharmaceutical preparations for the treatment of Rabies.
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/13/2026
PUBO
PUBLISHED FOR OPPOSITION
01/13/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/07/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/15/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/11/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/11/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/26/2025
GNRT
NON-FINAL ACTION E-MAILED
09/26/2025
CNRT
NON-FINAL ACTION WRITTEN
09/26/2025
DOCK
ASSIGNED TO EXAMINER
09/26/2025
MAFR
APPLICATION FILING RECEIPT MAILED
08/12/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/12/2025
NWAP
NEW APPLICATION ENTERED
08/12/2025
Continuous trademark protection
Get notified about every new filing that threatens KAMADA EACH LIFE IS UNIQUE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.